Represents the first FDA approved fixed-combination of tropicamide and phenylephrine for mydriasis Provides critical validation of key technology that is core to Eyenovia’s proprietary ...

The combination of cyclopentolate hydrochloride 0.2% and phenylephrine hydochloride 1% (Cyclomydril ®, Alcon, Ft. Worth, TX) delivers lower concentrations than separate instillations of ...

Glenmark has launched Olopatadine Hydrochloride Ophthalmic Solution, 0.1% (OTC). The company said its product compares to the active ingredient found in Pataday2 Twice Daily Relief.

Partnership co-promoting NovaBay’s Avenova ® Antimicrobial Lid & Lash Solution to large ophthalmic surgery centers along with one of Eyenovia’s FDA-approved product MydCombi™ Preparing for ...

About Eyenovia, Inc. Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic technology company commercializing MydCombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for ...

Glenmark Gets FDA Approval For Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) March 20, 2025 — 11:58 pm EDT Written by RTTNews.com for RTTNews -> ...

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2. ...

Glenmark Therapeutics Inc., USA (Glenmark) has launched Olopatadine hydrochloride ophthalmic solution USP, 0.1% (OTC); compare to the active ingredient in Pataday twice daily relief. According to ...

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic ...

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) ...